More compact doses for perioral treatment than for upper facial applications are used given that the oral musculature responds extra strongly to the same BTX-A dosing. Just one preparation of botulinum toxin type B (MyoBloc®/NeuroBloc®) exists. Its sole indicator and FDA acceptance lies in treatments of cervical dystonia. On https://botulinum-toxins40617.wikiap.com/1561952/rumored_buzz_on_botulinum_toxin_mechanism_of_action